CA-THE-MOPRIA-ALLIANCE
The Mopria® Alliance , a global non-profit organization providing universal standards and solutions for print and scan, today announced Android 11 includes new print capabilities and enhancements contributed by the Alliance in collaboration with the Google Android team.
A new “Share-to-Print” feature of the Android Default Print Service enables users to print images and documents from thousands of social media and productivity applications directly from their Android device. Practically any Android app that allows users to share files such as JPEG, BMP, PNG, GIF and PDF, now also includes a convenient and simple option to print those items as well.
Additionally, the “Share-to-Print” path for photo printing supports specific enhancements to ensure best fit and higher resolution on the printed page. These enhancements result in high-quality prints, regardless of aspect ratio of the photo or size of the print.
“With this update, we set out to integrate print features that would make the lives of mobile users easier and continue to push the envelope of what we can provide in the Default Print Service,” said Ingrid Kelly, Chairperson of the Board at the Mopria Alliance. “We achieved those goals in the Android 11 update, and we are excited to continue to invest in and demonstrate our commitment to providing an enhanced printing experience for Android users.”
For people wanting to maximize the features available in their printers that may not be supported by the Default Print Service, the update adds on-the-fly selection of other brand-specific print services and the Mopria Print Service . Users are able to select and install these additional print services directly in their print workflow to enable even more print features.
To date, Mopria print technology has been installed on more than 2 billion devices, including Windows PCs and laptops, Android phones and tablets, FireOS tablets and ChromeOS notebooks. Mopria print technology is designed to simplify desktop printing and mobile printing to more than 4,000 printer models and more than 120 million Mopria certified printers .
The Mopria Alliance membership represents many of today’s global printer businesses, OS providers, device manufacturers and software vendors. In addition to the founding companies, Canon, HP, Samsung and Xerox, Mopria Alliance members include Adobe, Brother, EFI, Epson, Fuji Xerox, Huawei, Konica Minolta, Kyocera, Lexmark, Microsoft, OKI Data, Pantum, Primax, Qualcomm, Ricoh, Toshiba, Xiaomi and YSoft.
The new Default Print Service features will be available to Android users who update to Android version 11. For the latest list of Mopria certified printers and print accessories, please visit https://mopria.org/certified-products .
About the Mopria® Alliance
The Mopria® Alliance is a non-profit membership organization of leading global technology companies with the mission of providing universal standards and solutions for print and scan. With a focus on mobility and modern productivity trends, Mopria technology is used to allow users to interact intuitively and seamlessly with a printer, multi-function printer or scanner, regardless of brand. Learn more at www.mopria.org . Print. Scan. Go.
Android is a trademark of Google Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom